Your browser doesn't support javascript.
loading
Psychedelic Experiences During the Early COVID-19 Pandemic: Findings From an International Online Survey.
Evens, Ricarda; Reiche, Simon; Marek, Roman M; Moon, Daa Un; Groß, Rosa Elisa; Romanello, Amy; Jalilzadeh Masah, Dario; Scicchitano Böckheler, Matteo; Gutwinski, Stefan; Montag, Christiane; Mick, Inge; Majic, Tomislav.
Afiliação
  • Evens R; Research Group Psychotropic Substances, Psychiatric University Clinic at Hospital St. Hedwig | CCM, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Reiche S; Department of Psychiatry and Neurosciences | CCM, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Marek RM; Research Group Psychotropic Substances, Psychiatric University Clinic at Hospital St. Hedwig | CCM, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Moon DU; Research Group Psychotropic Substances, Psychiatric University Clinic at Hospital St. Hedwig | CCM, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Groß RE; Interdisciplinary Research Group "The Future of Medicine: Good Health for All," Berlin-Brandenburg Academy of Sciences and Humanities, Berlin, Germany.
  • Romanello A; German Rheumatism Research Centre Berlin (DRFZ), Berlin, Germany.
  • Jalilzadeh Masah D; Department of Psychiatry and Neurosciences | CCM, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Scicchitano Böckheler M; Department of Psychiatry and Neurosciences | CCM, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Gutwinski S; Research Group Psychotropic Substances, Psychiatric University Clinic at Hospital St. Hedwig | CCM, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Montag C; Department of Psychiatry and Neurosciences | CCM, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Mick I; Berlin School of Mind and Brain, Humboldt-Universität zu Berlin, Berlin, Germany.
  • Majic T; Department of Psychiatry and Neurosciences | CCM, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Front Psychiatry ; 12: 732028, 2021.
Article em En | MEDLINE | ID: mdl-34803757
ABSTRACT

Introduction:

The current corona virus disease (COVID-19) pandemic has caused a serious global health crisis that has affected large parts of the public and private life worldwide, including the use of psychoactive substances. In this study, we investigated the effect of the COVID-19 pandemic on the use of serotonergic psychedelics, i.e., the settings in which people use psychedelics, the motives of usage, and the subjective quality of psychedelic experiences.

Methods:

The study was part of an international, cross-sectional, internet-based survey (N = 5,049) available in five languages (English, German, Spanish, Italian, and Korean) carried out during the early phase of the pandemic from April to August 2020. Participants were asked to retrospectively rate settings and motives of psychedelic substance use before the pandemic and in the last 4 weeks during the pandemic, as well as changes in psychedelic experiences.

Results:

Of n = 1,375 participants that reported the use psychedelics in 2019 or 2020, n = 642 (46.6%) also took psychedelics during the pandemic. During the pandemic, participants used psychedelics significantly less often in settings that were outside their home. Top motives to use psychedelics were comparable before and during the pandemic, but participants consumed less out of curiosity, to celebrate, or because friends took it, and more out of boredom. An increase in positively connoted, often pro-social experiences was observed. Two thirds of participants who used psychedelics during the pandemic claimed that psychedelics had helped them to deal better with the corona pandemic at least slightly.

Discussion:

Changes in setting and motives were mostly in line with restrictions caused by control measures to contain the spread of the virus. The unexpected increase in positively connoted experiences possibly reflects a favorable interaction of environmental macro- and individual micro-contexts during the pandemic (e.g., by reducing the use in more uncontrolled recreational settings or by encouraging a strong self-selection of substance users due to the expectation of "bad trips"). Increased pro-social feelings under psychedelics might reflect a desire for social interactions in times of social distancing and pandemic-related stress and anxiety.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article